GlaxoSmithKline Consumer Healthcare is Offering free Nicotine Lozenges to all licensed pilots after FAA banned Chantix anti-smoking drug usage due to side effects.
This week, the Federal Aviation Administration (FAA) announced it removed a prescription smoking cessation drug from the list of medications it considers safe for pilots and air-traffic controllers.
This followed a new analysis of adverse event data from the non-profit Institute for Safe Medication Practices which linked the medication to mental confusion and other problems that could put passengers at risk.
In response to this announcement, GlaxoSmithKline Consumer Healthcare is offering free nicotine replacement therapy in the form of nicotine lozenges to all licensed pilots now through June 30th.
This news is going to have a dramatic impact on pilots and air-traffic controllers who smoke.
Recent research, which shows that the 4mg nicotine lozenge has been clinically proven to help reverse the following symptoms associated with quitting smoking: difficulty concentrating, attention deficit, short-term memory deficit and selective attention deficit – some of the very issues at the core of the FAA’s ruling.
This information is in addition to the extensive studies that have shown nicotine replacement therapy reduces nicotine withdrawal symptoms, including difficulty concentrating.
Source: On Behalf of GlaxoSmithKline
Comment and add to the story without registration, but keep the comments meaningful please. Links are not accepted.
